Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IDRA

Idera Pharmaceuticals (IDRA) Stock Price, News & Analysis

Idera Pharmaceuticals logo

About Idera Pharmaceuticals Stock (NASDAQ:IDRA)

Key Stats

Today's Range
N/A
50-Day Range
$0.17
$7.23
52-Week Range
N/A
Volume
21,870 shs
Average Volume
464,030 shs
Market Capitalization
$450.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive IDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IDRA Stock News Headlines

Ekso Bionics (NASDAQ: EKSO)
If You Keep Cash In A U.S. Bank Account… Read This NOW
The Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of customer deposits as Americans rush into a new form of money… That’s just been authorized under President Trump’s highly controversial new law, S.1582.tc pixel
Kiniksa Pharmaceuticals
Nabriva Therapeutics AG (NBRVF)
Marginalia
See More Headlines

IDRA Stock Analysis - Frequently Asked Questions

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) released its earnings results on Monday, November, 8th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01.

Idera Pharmaceuticals's stock split before market open on Friday, November 25th 2022.The 2-1 split was announced on Friday, November 25th 2022. The newly minted shares were distributed to shareholders after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Idera Pharmaceuticals investors own include BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Sorrento Therapeutics (SRNE), Proteostasis Therapeutics (PTI), Dynavax Technologies (DVAX), Agenus (AGEN) and SCYNEXIS (SCYX).

Company Calendar

Last Earnings
11/08/2021
Today
10/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IDRA
CIK
861838
Employees
32
Year Founded
1989

Profitability

EPS (Trailing Twelve Months)
($0.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$98.09 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-68.74%
Return on Assets
-34.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.56
Quick Ratio
1.56

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
0.29
Book Value
$0.56 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
62,355,000
Free Float
59,206,000
Market Cap
$450.52 million
Optionable
Optionable
Beta
1.25

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:IDRA) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners